Microsulis sells microwave endometrial ablation technology to
21 Feb 2011
UK company Microsulis Medical Limited has announced that it is
to discontinue sales of its Microwave Endometrial Ablation (MEA) system
for gynaecology and female urology and has licensed the technology to
Microsulis says it will now concentrate on developing microwave
tumour ablation technology.
Microsulis CEO Stuart McIntyre said, “Following years of
investment and technical development in 2010 we achieved CE Mark and
FDA 510k clearance on our revolutionary high power Microwave Tumour
Ablation (MTA) system. This breakthrough system redefines the
performance benchmark for tumour ablation devices in the
interventional oncology market.
"Through the sale of our MEA platform to Hologic, we not only
open our microwave technology to the most capable device developer
in the woman’s health space, but we release the value of MEA to
underpin the commercialization phase of our MTA device.
“Hologic has the capability and market leadership needed to
release the potential of our microwave technology to treat various
female urological and gynecological conditions. There is no better
company to nurture the technology in the woman’s health space.”
Microsulis says it will continue to support existing MEA users
worldwide in using existing customer owned inventories of MEA
treatments, and will retain ownership of all its MEA equipment
including all systems and applicators currently on loan to users.